MapLight Therapeutics (MPLT) Interest Expenses (2024 - 2025)
MapLight Therapeutics (MPLT) reported Interest Expenses of $300000.0 for Q4 2025, up 200.0% on a YoY basis from $100000.0 in Q4 2024, and down 92.72% sequentially from $4.1 million in Q3 2025.
MapLight Therapeutics (MPLT) Interest Expenses (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Interest Expenses data on file, last reported at $300000.0 in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses rose 200.0% year-over-year to $300000.0; the trailing twelve-month figure through Sep 2025 stood at $4.1 million (changed N/A YoY), and the FY2025 full-year result was $12.6 million, up 1.11% from the prior year.
- Interest Expenses declined to $300000.0 in Q4 2025, from $4.1 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $4.1 million in Q3 2025 to a low of -$300000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 300,000.00 |
| Dec 31, 2025 | 300,000.00 |
| Sep 30, 2025 | 4.12 Mn |
| Sep 30, 2025 | 4.12 Mn |
| Dec 31, 2024 | -300,000.00 |
| Dec 31, 2024 | -300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |